These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7813812)

  • 1. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene.
    Panahloo A; Mohamed-Ali V; Lane A; Green F; Humphries SE; Yudkin JS
    Diabetes; 1995 Jan; 44(1):37-42. PubMed ID: 7813812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome.
    McCormack LJ; Nagi DK; Stickland MH; Mansfield MW; Mohamed-Ali V; Yudkin JS; Knowler WC; Grant PJ
    Diabetologia; 1996 Dec; 39(12):1512-8. PubMed ID: 8960834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes.
    Mansfield MW; Stickland MH; Grant PJ
    Thromb Haemost; 1995 Oct; 74(4):1032-4. PubMed ID: 8560407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction.
    Gray RP; Panahloo A; Mohamed-Ali V; Patterson DL; Yudkin JS
    Atherosclerosis; 1997 Apr; 130(1-2):171-8. PubMed ID: 9126661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
    Festa A; D'Agostino R; Rich SS; Jenny NS; Tracy RP; Haffner SM
    Circulation; 2003 May; 107(19):2422-7. PubMed ID: 12719278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.
    Nagi DK; McCormack LJ; Mohamed-Ali V; Yudkin JS; Knowler WC; Grant PJ
    Diabetes Care; 1997 Aug; 20(8):1304-9. PubMed ID: 9250459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus.
    Mansfield MW; Stickland MH; Grant PJ
    Thromb Haemost; 1995 Sep; 74(3):842-7. PubMed ID: 8571308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients.
    Testa R; Bonfigli AR; Sirolla C; Boemi M; Manfrini S; Mari D; Testa I; Sacchi E; Franceschi C
    Diabetes Nutr Metab; 2004 Aug; 17(4):217-21. PubMed ID: 15575342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
    Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
    Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study.
    Juhan-Vague I; Morange PE; Frere C; Aillaud MF; Alessi MC; Hawe E; Boquist S; Tornvall P; Yudkin JS; Tremoli E; Margaglione M; Di Minno G; Hamsten A; Humphries SE;
    J Thromb Haemost; 2003 Nov; 1(11):2322-9. PubMed ID: 14629464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene.
    Testa R; Bonfigli AR; Sirolla C; Marra M; Boemi M; Mari D; Sacchi E; Dolci A; Catalano A; Procopio A; Ceriello A
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):220-6. PubMed ID: 17433639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels.
    Zietz B; Buechler C; Drobnik W; Herfarth H; Schölmerich J; Schäffler A
    Endocr Res; 2004 Aug; 30(3):443-53. PubMed ID: 15554360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes.
    Margaglione M; Grandone E; Vecchione G; Cappucci G; Giuliani N; Colaizzo D; Celentano E; Panico S; Di Minno G
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2082-7. PubMed ID: 9351375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
    Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
    Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
    Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
    Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
    Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
    Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of PAI-1 gene promoter 4g/5g polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension.
    Jeng JR
    Am J Hypertens; 2003 Apr; 16(4):290-6. PubMed ID: 12670745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
    Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
    Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
    Kinik ST; Ataç FB; Verdi H; Cetintaş S; Sahin FI; Ozbek N
    Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.